Prevexxion RN+HVT+IBD RSS Authorised This medicine is authorised for use in the European Union infectious bursal disease / Marek's disease vaccine (live recombinant) Medicine Veterinary Authorised
Page contentsPage contents Overview Product information Product details Authorisation details Assessment history News on Prevexxion RN+HVT+IBD Topics Application under evaluation CVMP opinion European Commission decision OverviewUp-to-date information on this veterinary medicinal product is available on the Veterinary Medicines Information website. Prevexxion RN+HVT+IBD : EPAR - Medicine overview English (EN) (81.94 KB - PDF)First published: 15/04/2021 Last updated: 02/12/2024 View Other languages (25) български (BG) (93.36 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View español (ES) (81.97 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View čeština (CS) (93.99 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View dansk (DA) (83.34 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View Deutsch (DE) (82.76 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View eesti keel (ET) (82.18 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View ελληνικά (EL) (93.76 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View français (FR) (82.44 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View hrvatski (HR) (92.27 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View íslenska (IS) (83.29 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View Gaeilge (GA) (83.57 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View italiano (IT) (82.29 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View latviešu valoda (LV) (94.29 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View lietuvių kalba (LT) (94.03 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View magyar (HU) (94.15 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View Malti (MT) (95.95 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View Nederlands (NL) (82.05 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View norsk (NO) (82 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View polski (PL) (95.62 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View português (PT) (83.01 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View română (RO) (94.17 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View slovenčina (SK) (94.08 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View slovenščina (SL) (82.27 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View Suomi (FI) (81.54 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View svenska (SV) (82.05 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View Product information Prevexxion RN+HVT+IBD : EPAR - Product information English (EN) (81.49 KB - PDF)First published: 15/04/2021 Last updated: 02/12/2024 View Other languages (25) български (BG) (91.78 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View español (ES) (81.51 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View čeština (CS) (92.48 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View dansk (DA) (82.05 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View Deutsch (DE) (81.72 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View eesti keel (ET) (81.22 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View ελληνικά (EL) (91.79 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View français (FR) (81.63 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View hrvatski (HR) (91.56 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View íslenska (IS) (81.52 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View Gaeilge (GA) (81.36 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View italiano (IT) (81.76 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View latviešu valoda (LV) (92.14 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View lietuvių kalba (LT) (92.19 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View magyar (HU) (92.76 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View Malti (MT) (93.86 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View Nederlands (NL) (81.15 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View norsk (NO) (81.52 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View polski (PL) (93.22 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View português (PT) (82.53 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View română (RO) (91.73 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View slovenčina (SK) (81.75 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View slovenščina (SL) (81.76 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View Suomi (FI) (81.11 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View svenska (SV) (81.47 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View Prevexxion RN+HVT+IBD : EPAR - All authorised presentations English (EN) (81.94 KB - PDF)First published: 15/04/2021 Last updated: 02/12/2024 View Other languages (25) български (BG) (93.36 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View español (ES) (81.97 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View čeština (CS) (93.99 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View dansk (DA) (83.34 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View Deutsch (DE) (82.76 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View eesti keel (ET) (82.18 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View ελληνικά (EL) (93.76 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View français (FR) (82.44 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View hrvatski (HR) (92.27 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View íslenska (IS) (83.29 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View Gaeilge (GA) (83.57 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View italiano (IT) (82.29 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View latviešu valoda (LV) (94.29 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View lietuvių kalba (LT) (94.03 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View magyar (HU) (94.15 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View Malti (MT) (95.95 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View Nederlands (NL) (82.05 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View norsk (NO) (82 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View polski (PL) (95.62 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View português (PT) (83.01 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View română (RO) (94.17 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View slovenčina (SK) (94.08 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View slovenščina (SL) (82.27 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View Suomi (FI) (81.54 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View svenska (SV) (82.05 KB - PDF) First published: 15/04/2021 Last updated: 02/12/2024 View Product details Name of medicine Prevexxion RN+HVT+IBD Active substance Live recombinant Marek’s disease virus, serotype 1, strain RN1250; Live recombinant turkey herpesvirus, expressing the VP2 protein of infectious bursal disease virus, strain vHVT013-69 International non-proprietary name (INN) or common name infectious bursal diseaseMarek's disease vaccine (live recombinant) Pharmacotherapeutic groupImmunologicals for avesDomestic fowlavian herpes virus (marek's disease) + avian infectious bursal disease virus (gumboro disease) + newcastle disease virus/paramyxovirus Authorisation details EMA product number EMEA/V/C/005057 Assessment history Expand section Collapse section Changes since initial authorisation of medicine Prevexxion RN+HVT+IBD : EPAR - Procedural steps taken and scienfitic after authorisation English (EN) (81.94 KB - PDF)First published: 15/04/2021 Last updated: 02/12/2024 View CVMP post-authorisation summary of positive opinion for Prevexxion RN+HVT+IBDAdopted Reference Number: EMA/114981/2024 English (EN) (96.91 KB - PDF)First published: 18/03/2024 View Initial marketing authorisation documents Prevexxion RN+HVT+IBD : EPAR - Public assessment reportAdopted Reference Number: EMA/321394/2020 English (EN) (81.49 KB - PDF)First published: 15/04/2021 Last updated: 02/12/2024 View CVMP summary of positive opinion for Prevexxion RN+HVT+IBDAdopted Reference Number: EMA/CVMP/240518/2020 English (EN) (143.45 KB - PDF)First published: 25/05/2020 View News on Prevexxion RN+HVT+IBD Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 15-17 July 202518/07/2025 Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 3-5 December 202406/12/2024 Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 12-13 March 202418/03/2024 Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 15-16 May 202322/05/2023 Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 18-20 April 202321/04/2023 Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 6-8 September 202209/09/2022 Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 5-7 October 202108/10/2021 Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 18-20 May 202025/05/2020 Topics Medicines Vaccines This page was last updated on 02/12/2024 Share this page